Abstracts tagged "autoimmune diseases"

Abstract Number: 0204 • ACR Convergence 2021
Risk of Hepatitis B Virus Reactivation in Patients with Immune-Mediated Inflammatory Diseases Receiving Biologics: Focus on the Timing of Biologics After Prophylactic Anti-viral Agents
Soo Min Ahn¹, Jonggi Choi², Byong Duk Ye², Suk-Kyun Yang², Ji Seon Oh³, Yong-Gil Kim², Chang-Keun Lee², Bin Yoo¹, Sang Hyoung Park² and Seokchan Hong², ¹ASAN MEDICAL CENTER, Seoul, South Korea, ²Asan Medical Center, Seoul, Republic of Korea, ³Asan Medical Center, Ulsan, Republic of Korea
Background/Purpose: Prophylactic anti-viral therapy is required in patients with hepatitis B virus (HBV) infection receiving biologics because of the high risk of HBV reactivation. However,…
Abstract Number: 0458 • ACR Convergence 2021
Single Cell Profiling Reveals a Wnt-mediated Transcriptional Gradient That Drives Inflammation in Rheumatoid Arthritis Synovial Fibroblast Pathology
Alisa Mueller¹, Angela Zou¹, Emily Taylor², Triin Major², David Gardner³, Adam Croft⁴, Roche Fibroblast Network Consortium⁵, Andrew Filer², Christopher Buckley⁶, Kevin Wei¹, Ilya Korsunsky¹, Soumya Raychaudhuri¹ and Michael Brenner⁷, ¹Brigham and Women's Hospital, Boston, MA, ²University of Birmingham, Birmingham, United Kingdom, ³University of Birmingham, College of Medical and Dental Sciences, Birmingham, United Kingdom, ⁴University of Birmingham, Halesowen, United Kingdom, ⁵Roche Innovation Center Basel, Basel, Switzerland, ⁶University of Oxford, Oxford, United Kingdom, ⁷Brigham and Women's Hospital, Harvard Medical School, Newton, MA
Background/Purpose: Synovial fibroblasts are key inflammatory aggressors in rheumatoid arthritis (RA) that mediate cartilage and bone destruction, yet therapies directly targeting these cells are lacking.…
Abstract Number: 0695 • ACR Convergence 2021
Safety and Tolerability of IVIg (Octagam 10%) in Patients with Active Dermatomyositis. Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial
Rohit Aggarwal¹, Christina Charles-Schoeman², Joachim Schessl³, Zsuzsanna Bata-Csorgo⁴, Mazen Dimachkie⁵, Zoltan Griger⁶, Sergey Moiseev⁷, Chester Oddis¹, Elena Schiopu⁸, Jiri Vencovsky⁹, Irene Beckmann¹⁰, Elisabeth Clodi¹⁰, Todd Levine¹¹ and and the ProDERM Investigators¹², ¹University of Pittsburgh, Pittsburgh, PA, ²Department of Medicine, University of California, Los Angeles, Los Angeles, CA, ³Friedrich-Baur-Institut/Medical University Munich, München, Germany, ⁴University of Szeged, Faculty of Medicine, Szeged, Hungary, ⁵University of Kansas Medical Center, Kansas City, KS, ⁶University of Debrecen, Debrecen, Hungary, ⁷First Moscow State Medical University, Moscow, Russia, ⁸University of Michigan, Ann Arbor, MI, ⁹Institute of Rheumatology, Prague, Czech Republic, ¹⁰Octapharma PPG, Vienna, Austria, ¹¹Phoenix Neurological Associates, LTD, Phoenix, AZ, ¹²Different Institutions in several countries, Vienna, Austria
Background/Purpose: Dermatomyositis (DM) is a chronic systemic autoimmune disease with characteristic skin rash and muscle weakness. Intravenous immunoglobulin (IVIg) has long been used as adjuvant…
Abstract Number: 1026 • ACR Convergence 2021
Factors Impacting Likelihood of Discontinuing Immunosuppression in Adult Dermatomyositis: A Single-Center Study
Sung Kyung Cho¹, Lorinda Chung² and David Fiorentino³, ¹University of Texas Southwestern, Dallas, TX, ²Stanford University, Palo Alto, CA, ³Stanford University, Redwood City, CA
Background/Purpose: Dermatomyositis (DM) is a chronic idiopathic inflammatory myopathy with variable clinical course, but little is known regarding factors associated with remission of disease. We…
Abstract Number: 1303 • ACR Convergence 2021
Associations Between Early Changes in Circulating B Cell Subsets and Severe Flare in Systemic Lupus Erythematosus – Results from Three Phase III Trials of Belimumab
Ioannis Parodis¹, Alvaro Gomez², Julius Lindblom², Alexander Borg², Sharzad Emamikia² and Mariele gatto³, ¹Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden and Department of Rheumatology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden, ²Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ³Department of Rheumatology, University of Padua, Padua, Italy
Background/Purpose: Belimumab is the only approved targeted treatment for systemic lupus erythematosus (SLE). Identification of early predictors of response or non-response to therapy is imperative…
Abstract Number: 1518 • ACR Convergence 2021
Elucidating Activated Osteoarthritis as an Emerging Immune Checkpoint Inhibitor Toxicity: A Descriptive Observational Study
Pankti Reid¹, David Liew², Rajshi Akruwala³, Anne Bass⁴ and Karmela Kim Chan⁵, ¹University of Chicago Medical Center, Chicago, IL, ²Austin Health, Heidelberg, Australia, ³SUNY Downstate Health Sciences University College of Medicine, Brooklyn, NY, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁵Hospital for Special Surgery, New York, NY
Background/Purpose: Immune checkpoint inhibitors (ICIs) are a type of immunotherapy used for cancer management. ICI toxicities can challenge the ability to safely continue ICI therapy…
Abstract Number: 1606 • ACR Convergence 2021
Telemedicine for Rheumatology Care During the COVID-19 Pandemic: Patient Perceptions and Preferences
Maria I. Danila¹, Kelly Gavigan², Esteban Rivera², William Nowell², Michael George³, Jeffrey Curtis⁴, Lisa Christopher-Stine⁵, Shubhasree Banerjee³, Peter Merkel³, Kalen Young⁶, Dianne Shaw⁶, Jennifer Gordon⁶ and Shilpa Venkatachalam², ¹University of Alabama at Birmingham, Birmingham, AL, ²Global Healthy Living Foundation, Upper Nyack, NY, ³University of Pennsylvania, Philadelphia, PA, ⁴Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁵Johns Hopkins University, Baltimore, MD, ⁶Vasculitis Foundation, Kansas City, MO
Background/Purpose: The COVID-19 pandemic disrupted the delivery of medical care and resulted in a substantial uptake in telemedicine care for patients with chronic conditions, including…
Abstract Number: 1769 • ACR Convergence 2021
BMS-986256, an Oral Novel Toll-like Receptor 7 and 8 (TLR7/8) Inhibitor, Does Not Affect the Pharmacokinetics of Mycophenolate Mofetil in Healthy Subjects
Manoj Chiney¹, Ihab Girgis², Melanie Harrison¹, Xiaoping Zhang¹, Yun Shen³, Michelle Dawes¹, Lixian Dong², Diane Shevell³, Urvi Aras¹ and Bindu Murthy³, ¹Bristol Myers Squibb, Lawrenceville, NJ, ²Bristol Myers Squibb, Princeton, NJ, ³Bristol Myers Squibb, Lawrenceville
Background/Purpose: Toll like receptor (TLR) 7 and TLR8 are activated as part of the disease pathophysiology of systemic lupus erythematosus (SLE), including lupus nephritis (LN),…
Abstract Number: 1750 • ACR Convergence 2020
Longitudinal Change in the Central Nervous System Pain Response After Treatment with Certolizumab or Placebo. a Post-hoc Analysis from the Pre-CEPRA Trial
Juergen Rech¹, Hannah Schenker², Koray Tascilar¹, Melanie Hagen², Larissa Valor Mendez², Verena Schoenau³, Marina Sergeeva⁴, Jutta Prade⁴, Mageshvar Sulvakumar⁵, Laura Konert⁶, Arnd Kleyer¹, David Simon¹, Sandra Strobelt⁴, Frank Behrens⁷, Christoph Baerwald⁸, Stephanie Finzel⁹, Reinhard Voll¹⁰, Axel Hueber¹¹, Eugen Feist¹², Julie Roesch¹³, José A. P. da Silva¹⁴, Arnd Doerfler¹³, Nemanja Damjanov¹⁵, Andreas Hess¹⁶ and Georg Schett¹⁷, ¹Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ²Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, Germany, ³Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, ⁴Institute for Experimental Pharmacology, Erlangen, Germany, ⁵Insitute for Experimental Pharmacology, FAU Erlangen-Nuremberg, Erlangen, Germany, ⁶Institute for Experimental Pharmacology, FAU Erlangen-Nürnberg, Erlangen, ⁷CIRI/Rheumatology & Fraunhofer TMP, Goethe University, Frankfurt, Germany, ⁸Uniklinik Leipzig, Medizinische Klinik III - Bereich Rheumatologie, Leipzig, Germany, ⁹Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Freiburg, Germany, ¹⁰Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Freibrug, ¹¹Section Rheumatology, Sozialstiftung Bamberg, Bamberg, Germany, ¹²Department of Rheumatology, Helios Vogelsang-Gommern, Vogelsang-Gommern, Germany, ¹³Abteilung für Neuroradiologie, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, Germany, ¹⁴9.Centro Hospitalar e Universitário Coimbra (Rheumatology Department), Coimbra, Portugal, Coimbra, Portugal, ¹⁵Belgrade University School of Medicine, Belgrade, Serbia, ¹⁶Institute for Experimental Pharmacology, Erlangen, ¹⁷Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany
Background/Purpose: Biologicals - bring a hope of recovery or amelioration to people suffering from RA, but only half of the patients respond to such treatment.…
Abstract Number: PP05 • ACR Convergence 2020
Coping Through Advocacy – My Story Living with Relapsing Polychondritis
Allegonda Imeson¹, ¹The Canadian Society for Relapsing Polychondritis, Stony Plain, AB, Canada
Background/Purpose: Becoming a mother was the most pivotal moment of my life. From early on, I instilled the importance of a physical, healthy lifestyle for my two…
Abstract Number: 0035 • ACR Convergence 2020
Distinct Biological Pathways in Both Blood and Kidney Further Define Molecular Profiles Across Diverse Nephritides
Loqmane Seridi¹, Matteo Cesaroni¹, Qingxuan Song², Ashley Orillion¹, Frédéric Baribaud¹, Tatiana Ort¹, Sheng Gao², Tomas Parker³, James Chevalier³, Dan Levine³, Alan Perlman³ and Jarrat Jordan¹, ¹Janssen Research & Development, LLC, Spring House, PA, ²Janssen Research & Development, LLC, Spring House, PA, USA, Spring House, PA, ³The Rogosin Institute, New York Presbyterian Hospital-Weill Medical College of Cornell University New York, NY, USA., New York, NY
Background/Purpose: Approximately 40% of SLE patients will develop Lupus Nephritis (LN), of which 10-30 % will progress to end-stage renal disease. To further understand LN…
Abstract Number: 0395 • ACR Convergence 2020
African Ancestry-Specific Variants Regulate TGFB3 Expression in Systemic Sclerosis
Julia Hartman¹, Andrea Conte², Chloe Borden³, Urvashi Kaundal⁴, Yongbing Zhao², Sarah Safran⁵, Ami Shah⁶, Maureen Mayes⁷, Ayo Doumatey⁸, Amy Bentley⁹, Daniel Shriner⁸, Robyn Domsic¹⁰, Thomas Medsger¹¹, Paula Ramos¹², Richard Silver¹³, Virginia Steen¹⁴, John Varga¹⁵, Vivien Hsu¹⁶, Lesley Ann Saketkoo¹⁷, Elena Schiopu¹⁸, Dinesh Khanna¹⁹, Jessica Gordon²⁰, Lindsey Criswell²¹, Heather Gladue²², Chris Derk²³, Elana Bernstein²⁴, S. Louis Bridges²⁵, Victoria Shanmugam²⁶, Kathleen Kolstad²⁷, Lorinda Chung²⁸, Suzanne Kafaja²⁹, Reem Jan³⁰, Marcin Trojanowski³¹, Avram Goldberg³², Benjamin Korman³³, Monique Hinchcliff³⁴, Settara Chandrasekharappa⁸, Stefania Dell'Orso³, Adebowale Adeyemo⁸, Charles Rotimi⁸, Elaine Remmers³⁵, Fredrick Wigley³⁶, Daniel Kastner³⁵, Francesco Boin³⁷, Rafael Casellas² and Pravitt Gourh⁴, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Washington, DC, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Bethesda, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, New York, NY, ⁶Johns Hopkins University School of Medicine, Ellicott City, MD, ⁷University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, ⁸National Human Genome Research Institute, Bethesda, ⁹National Human Genome Research Institute (NHGRI), NIH, Bethedsa, MD, ¹⁰University of Pittsburgh School of Medicine, Pittsburgh, PA, ¹¹University of Pittsburgh School of Medicine, Verona, PA, ¹²Medical University of South Carolina, Charleston, SC, ¹³Medical University of South Carolina, Charleston, ¹⁴Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ¹⁵Northwestern University, Chicago, IL, ¹⁶Rutgers-RWJ Medical School, South Plainfield, NJ, ¹⁷Scleroderma Patient Care and Research Center, Tulane University, New Orleans, LA, ¹⁸Michigan Medicine, Ann Arbor, MI, ¹⁹University of Michigan, Ann Arbor, MI, ²⁰Hospital for Special Surgery, New York, NY, ²¹Rosalind Russell/Ephraim P. Engleman Rheumatology Research Center, University of California San Francisco, San Francisco, CA, ²²Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, NC, ²³University of Pennsylvania, Philadelphia, PA, ²⁴Columbia University, New York, NY, ²⁵University of Alabama at Birmingham, Mountain Brk, AL, ²⁶The George Washington University, Washington, DC, ²⁷Division of Immunology & Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ²⁸Stanford University School of Medicine and Palo Alto VA Health Care System, Palo Alto, CA, ²⁹David Geffen School of Medicine, UCLA, Los Angeles, CA, ³⁰Pritzker School of Medicine, University of Chicago, Chicago, IL, ³¹Boston University Medical Center, BOSTON, MA, ³²NYU Langone Medical Center - NYU Hospital for Joint Diseases, Lake Success, NY, ³³Department of Medicine, University of Rochester Medical Center, Rochester, NY, ³⁴Yale School of Medicine, Westport, CT, ³⁵National Human Genome Research Institute (NHGRI), NIH, Bethesda, MD, ³⁶Johns Hopkins University School of Medicine, Baltimore, MD, ³⁷University of California San Francisco, Cedars-Sinai, West Hollywood, CA
Background/Purpose: African American (AA) patients have a higher prevalence of SSc than European Americans (EA). Adding to this health disparity, AA SSc patients are more…
Abstract Number: 0595 • ACR Convergence 2020
High Satisfaction with Tele-medicine in a New York City Clinic
Tommy Chen¹, Cathy Guo¹, Wei Tang¹, Leila Khalili¹ and Anca Askanase², ¹Columbia University Medical Center, New York, NY, ²Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: The face of medicine is changing with the time. A twenty-first century technological revolution in medicine happened in March 2020 as the COVID-19 pandemic…
Abstract Number: 0862 • ACR Convergence 2020
Voclosporin Does Not Decrease Mycophenolic Acid Concentrations in Patients with SLE
Teun van Gelder¹, Robert Huizinga², Neil Solomons² and Laura Lisk³, ¹Leiden University Medical Centre, Leiden, Zuid-Holland, Netherlands, ²Aurinia Pharmaceuticals, Victoria, BC, Canada, ³Aurinia Pharmaceuticals Inc., Victoria, BC, Canada
Background/Purpose: Voclosporin (VCS) is a novel calcineurin inhibitor, structurally similar to cyclosporine A (CsA). In a Phase 3 clinical trial in patients with active lupus…
Abstract Number: 1052 • ACR Convergence 2020
Connective Tissue Disease-Related Interstitial Lung Disease in American Indian/Alaska Native People in Alaska
Joanna Marco¹ and Elizabeth Ferucci², ¹University of Washington, Seattle, WA, ²Alaska Native Tribal Health Consortium, Anchorage, AK
Background/Purpose: Many connective tissue diseases are known to cause interstitial lung disease (ILD). American Indian/Alaska Native (AI/AN) populations have higher prevalence and severity of a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].